ArticleJournal of cardiothoracic surgery2026
Intracoronary prourokinase for coronary embolism after aortic valve replacement: a viable treatment option?
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCoronary embolism (CE) is a rare but life-threatening cause of acute myocardial infarction (AMI) in patients following mechanical aortic valve replacement (AVR), often resulting from subtherapeutic anticoagulation. Due to the absence of consensus management guidelines, treatment strategies remain individualized. CASE PRESENTATION: A 67-year-old man with a history of mechanical AVR presented with inferior ST-segment elevation myocardial infarction after discontinuing warfarin for one week, resulting in subtherapeutic anticoagulation. Emergency coronary angiography revealed abrupt occlusion of the mid-right coronary artery (RCA) without underlying atherosclerosis. Targeted intracoronary administration of 20 mg recombinant human prourokinase (rh-proUK) via a microcatheter enabled effective thrombus aspiration and complete restoration of TIMI 3 flow without residual stenosis, thereby avoiding stent implantation.
conclusionThis case demonstrates that intracoronary rh-proUK administration serves as an effective rescue therapy for refractory CE when conventional interventions fail, enabling stent-free revascularization. The findings also underscore the importance of strict lifelong anticoagulation in patients with mechanical valves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.